Radiopharm Theranostics Limited

Healthcare · Biotechnology · Australia

Last price 1.1164 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 12.21M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also...